🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
0.2342
-0.0300 (-11.36%)
At close: Nov 20, 2026, 4:00 PM EST
0.238543
+0.0043 (1.85%)
After-hours: Nov 20, 2026, 7:54 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

DURAVYU’s wet AMD Phase III trials missed their primary endpoints, shifting the focus to DME. Management cited Phase II results, repeat-dose safety and a six-month delivery profile as strengths, with pivotal data targeted for early Q4 2027.

Moderator

Got it. All right. Good afternoon, everyone. Thank you for joining. My name is Pascal Kashi, I'm one of the Senior Biotech Analysts at Jefferies. We're here in London at the Jefferies Global Healthcare Conference. Really pleased to have this today, the management team of EyePoint, joined by Dr. Jay Duker and George Elston, CEO and CFO, respectively, of the company. Jay, could you just kick us off with a little bit of an intro to the company?

Jay Duker
CEO, EyePoint

Of course, and thanks very much for inviting us. We're really happy to be here. EyePoint is a drug delivery company to the back of the eye. Our lead asset is called DURAVYU. DURAVYU is the combination of a small molecule tyrosine kinase inhibitor called vorolanib. Vorolanib has activity against all the VEGF receptors, as well as PDGF, and as well as JAK1, giving it an anti-inflammatory component. It's in our patented delivery system, and the sustained release delivery system is able to deliver the drug with an intravitreal injection to last at least six months or longer in almost all patients. The drug is shipped and stored at room temperature, and the inserts are now created so that they're 95% drug, only 6% matrix, and the matrix is fully bioerodible.

We're currently still essentially in four phase III trials, two in wet AMD and two in diabetic macular edema, DME. Although, I'm sure people who've been following us know that we've reported on the top line of the wet AMD trials, the first one in August and the second one in October. And while the secondary endpoints look quite good, the primary endpoints in both trials were missed. As a result, we're in the process of closing the wet AMD trials and going forward as a DME-only company for the time being.

Moderator

Got it. Can you talk to us about, we'll get into more specifics, but just starting high level, what gives you confidence in DME after the wet AMD experience?

Jay Duker
CEO, EyePoint

Sure. DME, while a VEGF-mediated disease, is a different pathophysiology. DME is created by damage to the retinal blood vessels that result in their leakage. Wet AMD is the growth of new blood vessels from the choroid, the level below the retina, and probably inflammation plays more of a role than ischemia does. We know that wet AMD is primarily a VEGF-mediated disease. Anti-VEGFs control the disease and fluid quite rapidly, whereas in DME, the responses are variable. In fact, if you look at the label, for example, two milligram EYLEA in wet AMD, it's a three-injection monthly load followed by every other month. It's five-injection load in DME, I think confirming that it takes more treatment time to see improvement in DME. Also, this whole inflammatory component for DME has been known for many years. Intravitreal corticosteroids work quite well in diabetic macular edema.

In fact, studies that are done in eyes that are already pseudophakic, meaning they've had cataract surgery already, show similar results with intravitreal steroids as they do with anti-VEGFs. Just recently, Merck showed data for their Wnt agonist, which was non-inferior in DME to LUCENTIS. The point being that drugs that don't primarily affect the VEGF pathway can be successful in DME. That's the first part, I would say, is pathophysiologically. Secondly, we've got some pretty good preclinical data and some indirect clinical data that our drug, vorolanib, has an anti-inflammatory effect through JAK1 receptor, which blocks the downstream effects of IL-6. IL-6 is the cytokine that's been implicated in the inflammation in DME. It doesn't play nearly as big a role in wet AMD.

Again, we've shown in preclinical models that vorolanib at doses that we're achieving in humans is able to show that anti-inflammatory aspect. In humans, we studied DME in our phase II VERONA trial. The VERONA trial enrolled only patients who had active DME, meaning they had decreased vision and they had fluid on optical coherence tomography. The study results showed that at the end of the trial, 24 weeks, against EYLEA 2 mg, we were non-inferior. Both groups gained about seven letters. However, the fluid control was significantly better in the DURAVYU arm, and the fluid control and the vision gains were better at week four. As early as week four, the DURAVYU eyes had better vision and drier retinas than did the EYLEA arm. These results really give us confidence, along with some of the other secondary endpoints.

For example, we looked at leakage from the capillaries. That can be looked at in a quantitative fashion using fluorescein angiography. In a dose-dependent fashion, the DURAVYU eyes had less leakage than did the EYLEA eyes at the end of the trial. If you just ask the binary question at the end of the trial, was there still diabetic macular edema present or not, about half of the DURAVYU eyes had no DME at the end of the trial, where 100% of the control eyes still had some degree of DME. Those findings, I think, really also give us confidence in the DME result. I'll go back to the wet AMD result. I mentioned the secondary endpoints, and we did, I think, remarkably well with the secondary endpoints. First of all, with safety, we dosed almost 450 patients with repeat dosing.

The patients got dosed every six months, so we have data on safety with repeat dosing, and the safety looks quite good. We really believe that we have checked the safety box also now for DME. In addition, there was a significant reduction in treatment burden. Both studies showed that the DURAVYU arms, if in the real world the same type of treatment was applied, we would have on average two fewer injections per year than on-label EYLEA. When you look at the new generation, the second generation anti-VEGFs like high-dose EYLEA and VABYSMO, on average, they appear to be reducing the treatment burden by about one injection a year. Again, if approved and available, we think DURAVYU has the opportunity to do a little bit better than that. Finally, the fluid control. Despite missing the primary endpoint, we control fluid quite well.

That is measured on OCT, central subfield thickness. Normal is around 325 microns. The pooled data from the two trials showed that we were only about 10 microns worse than EYLEA, which is an insignificant amount. I do want to remind everybody, the DURAVYU eyes did gain vision. So it seems to be, of course, a binary result where you either hit the primary or you did not. But in a non-inferiority trial, remember, we just needed to come closer than we came. So when you think about it, if our eyes had gained another letter and a half, or the EYLEA eyes had lost another letter and a half, we would have been non-inferior. So it is not such a binary result in DME.

I think what you need to believe is our drug will work better in DME than it did in this wet AMD population, and that will be enough to get us to non-inferiority.

Moderator

Remind us on VERONA, just to be clear, that was a monotherapy study?

Jay Duker
CEO, EyePoint

One single injection. Is that what you're asking?

Moderator

Yeah.

Jay Duker
CEO, EyePoint

Yes.

Moderator

Like, there's no aflibercept load?

Jay Duker
CEO, EyePoint

There was no load. There was one injection of aflibercept, and that is another difference from the studies we had run before, all of which included a three-monthly dose load. The way the study was designed, we actually had two doses of DURAVYU, 2.7 mg and 1.34 mg. At the beginning of the study, all eyes got a shot of EYLEA, and then 30 minutes later, they either got a sham or they got our drug. Over 70% of the DURAVYU eyes went the length of the trial with no other injections, though. I might add, those eyes, if you look at the subgroup analysis for the DME trial, those eyes did great. They gained over 10 letters and had about 120 microns less fluid. The supplement-free eyes, it worked really well in DME.

Moderator

Got it. Can you talk about the size of the phase II VERONA experience and what gives you comfort that this can be recreated in a much larger phase III?

Jay Duker
CEO, EyePoint

The size of the trial, there were 11 eyes randomized into the 2.7 mg arm, 10 eyes in the 1.34 mg arm, and six eyes in the control arm.

Moderator

Got it. I guess, how do you think about risk profile, like for investors, of kind of extrapolating from a pretty limited sample size to a big phase III program?

Jay Duker
CEO, EyePoint

I believe that that often is the case. I mean, there are certainly drugs in other indications, and some even in retina, where a phase II trial is not performed. On the other hand, I think the confidence here is not just, you can say the end of the trial was small, and I will not disagree, but the OCT results, which show reduction in fluid, mirrored the visual acuity results. When the visions improved, the OCTs improved as well, and they went almost as a mirror image. I think that, to me, is strong evidence that the visual acuity results were real, because the structure and the function followed.

Moderator

Got it. Okay. For the phase III program, I think you mentioned that it's 75% treatment-naive. How should we think about the patient split and the implication of that?

Jay Duker
CEO, EyePoint

That's, for the last couple of approvals, that's been pretty much the split for DME, so that's not out of the ordinary, about 75% treatment-naive and 25% previously treated. That was the same split we had in the wet AMD trial. The bottom line for really the phase IIIs in retina is you have to enroll patients that have active disease. If a patient has had previous treatment and they have no fluid, they can't get into the trial. In our trial, the previously treated patients had to have a washout period of eight weeks prior to enrollment, and they had to have a certain amount of fluid and decreased vision to get into the trial. Also, of course, there's no washout period in the naive, but the same applies.

Therefore, we have reason to believe that they would behave similarly, and that's been true when you look at the prior trials done on DME with the anti-VEGFs. There hasn't been a marked difference in the response between the naive and the previously treated.

Moderator

Got it. Then, going beyond the study itself, I know in a real-world setting, you're seeing a lot more use of high-dose EYLEA and VABYSMO as well. How do you think about beyond the trial, the commercial benchmarks, and what you'd have to show to have a relevant spot?

Jay Duker
CEO, EyePoint

Well, I do want to remind everyone, if you do a non-inferiority trial in wet AMD or DME, you only have two choices as to your control group, according to the FDA. You can use on-label LUCENTIS or on-label two milligram EYLEA. That is what you have to go up against. The truth is, retinal specialists know really well how that control group acts, and it is pretty easy then if you are going up against an on-label two milligram EYLEA to be able to extrapolate the results to the real world. While I said this earlier, the second-generation drugs like VABYSMO and high-dose EYLEA are giving us a little more longevity, it is on average, when you look at the real-world data, it is probably about one fewer injection a year. Therefore, the ability to do better than that, I still think leaves a potentially huge market.

Remember also, 40% of the DME patients drop out of treatment after a year, because of the intensity of treatment. Just because on average patients require one fewer injection, there is still a lot of patients out there who require monthly injections, at least for a while, before they are under control. I think that gives us another opportunity, especially if the immediacy of the vision improvement, in the immediacy of the fluid effect that we saw in the phase II. If we replicate that in the phase III, I think that would put us in a very good stead for commercial success.

Moderator

Got it. How do you think about the kind of A lot of the drugs that have been successful in this space, they have been successful because they are able to market across at least a couple of indications. How would you frame kind of the long-term impairment or not of the asset of not being able to get there in wet AMD?

Jay Duker
CEO, EyePoint

It is an interesting question, and while we have certainly done some background research on that, we still think that the potential for a true sustained release in DME only is still great. I can remind people, across the world, DME is currently about a $5 billion market per year. In the U.S., it is about $3 billion. Yet a lot of patients remain undertreated because of the treatment burden, and we can help with that.

Remember also, we've never talked about DURAVYU being an either/or, meaning we're not ever saying, "Retina specialists, get rid of your high-dose EYLEA, your VABYSMO, your 2mg EYLEA, your biosimilars, and just use our drug." There is a load at the beginning, and there will be patients who either require or doctors will choose to add a biologic, and they may choose to add a biologic periodically if they believe that there's synergy. Therefore, I think that a drug like ours would expand the market, and not necessarily swap market share from one to the other. We offer something that those drugs can't do, which is consistent drug release for six months or longer.

Moderator

Got it. With respect to kind of like the operations of the trial itself, can you comment on, is there a futility analysis in the studies, or should there be?

Jay Duker
CEO, EyePoint

There is not. We're not doing any early looks to the DME trial. First of all, the trial's enrolled in about five months, and so if one were to take a look early, you'd be pretty close to the end of the trial anyway. That's the first thing. The second thing is, what you may see may be misleading. If you look at our LUGANO, which was the first wet AMD trial, at 40 weeks, we were non-inferior. Had we looked early at 36 or 40 weeks, we might have gotten the wrong impression as to what the end result was going to be. That early look or futility analysis is not something that would make sense to give up the alpha in a study like ours.

Moderator

Got it. Okay, makes sense. I know you talked about the experience from LUGANO and LUCIA, especially the result that you saw in the secondary endpoints as well. Is there anything else you wanted to add on kind of reflecting on LUGANO and LUCIA, what could have gone different, and importantly, the read through DME?

Jay Duker
CEO, EyePoint

Yeah, there are two parts to that. The first part is something that we're working on, is what could be done differently if we were to resurrect wet AMD as an indication. In both of the wet AMD trials, over half the patients went the full trial after the load with our drug alone, so got no supplements. The pooled data of that group of patients, which was over 50% of the patients, was non-inferior to the EYLEA eyes that were supplement-free. Again, if we could find a biomarker or something that would indicate to us at the beginning who those patients are, and we were to run a third trial, it would be obviously much more likely to be successful.

Read through to DME, however, given that the DME trial's already fully enrolled, and should read out early in the first quarter of next year, it would be a little late to make any significant changes. But we have reported that we did alter the supplement criteria somewhat in the DME trial. We're supplementing at five-letter decrease from best on study and 50 microns increase of fluid on OCT from best on study. That's a little tighter than what it was prior.

Moderator

Got it. Okay. George, can I ask you to talk about cash runway considerations, what the company has done to try to get to the readout, and what the company yet needs to do?

George Elston
CFO, EyePoint

Yeah, so we announced our earnings for Q3 last week. We ended September with $118 million of cash. Historically, our cash guidance had been into Q4. I think as everyone's aware, on the heels of the LUCIA data, we announced a reorganization, where we reduced the company headcount by 53%+ . We're actually actively evaluating our burn over the next 12 months to make that cash last to and through data. It's a simple story with EyePoint at the moment. We're people and we're clinical trials, so we're looking very closely at that. I think most important, we have our own manufacturing facility where we have done a thorough validation of the process and preparation for NDA.

While our reductions were across the board, we are really looking to make sure we maintain, number one, our ability to continue to execute on the trials and deliver the data in Q4 of next year. By the way, our guidance did update a little bit. We said early Q4 of 2027.

Moderator

Yeah.

George Elston
CFO, EyePoint

To make sure that that commercial facility remains in support of a potential NDA filing for DME.

Moderator

Got it. Okay. Jay, given that we have you here, you are a KOL in the field as well.

Jay Duker
CEO, EyePoint

In my former life, yes, I was.

Moderator

But you still treat patients though, right?

Jay Duker
CEO, EyePoint

I do.

Moderator

Yeah. Can I just ask, taking a step back from EyePoint and everything that's kind of been going on, as you look broadly across wet AMD and DME, across these different kind of modalities of better biologics, TKIs, gene therapy, other things I'm sure I'm forgetting in the landscape, can you just give us a little bit of a rundown of how you're seeing the space and pros and cons of different things?

Jay Duker
CEO, EyePoint

I'm going to say probably the same things I've been saying for many years. The two big unmet needs in retina is longevity of action, sustained release, and new MOAs. I think we're finally at the cusp of seeing both of those in reality. I think one could argue that we have a second MOA now with VABYSMO, and its Ang-2 effect. But obviously, we're seeing bispecifics and trispecifics in the pipeline. The question again will be, how much of a benefit are they? Are they going to be splitting the pie already, or are they going to be adding to the pie because they actually do something better? Delivery systems, again, we've chosen a small molecule with a sustained release delivery system. We've also had an approved sustained release system for a while, which is port delivery, but it's not really in wide use.

We have gene therapies that people are looking at, which are also true sustained release. The second-generation molecules are really more extended duration, meaning you give them a shot, it's first-order kinetics, and they gradually run out. But the truth is, 20% of wet AMD patients still need monthly injections, even with the second-generation drugs. I think those are the two areas that, after many years, I think we're finally starting to see some progress. But we have great drugs now. They just don't last very long.

Moderator

Yeah. Got it. All right. I think that's most of the questions that I had. I just wanted to thank you guys for being here. Jay and George, any closing remarks you'd like to leave the audience with?

George Elston
CFO, EyePoint

No, I think, as Jay covered, our confidence in DME is multifold because of the phase II VERONA data, the multi-MOA that DURAVYU brings through vorolanib, which is both the anti-VEGF and the anti-IL-6 activity. It's that type of a disease that we're treating, a multimodality. We did take some great learnings from LUGANO LUCIA. I think we feel pretty confident on safety, that box is checked with redosing. We controlled fluid really well in that trial, and I think that's a good read-through into DME as well, because that fluid control is a really important factor for that disease. We have a good history of delivering, and we're going to continue to focus on our cash and get a pathway to data, because we think this is ultimately going to be a great drug for patients if approved.

Moderator

Got it. George, can I just ask, I know you guys are kind of evaluating a lot right now. When should investors expect an update on cash runway and kind of bridging to the data?

George Elston
CFO, EyePoint

Well, we just gave an update last week. I think as we go into the new year, we are actively evaluating a range of forward programs for EyePoint. Stay tuned in the new year, I think is probably the best next update for that.

Moderator

Got it. Awesome. Well, thank you, Jay. Thank you, George Elston, for being here. Really appreciate it.

Jay Duker
CEO, EyePoint

Thanks, Chris.

George Elston
CFO, EyePoint

Appreciate it. Thank you.